WO2010106788A1 - 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 - Google Patents
妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 Download PDFInfo
- Publication number
- WO2010106788A1 WO2010106788A1 PCT/JP2010/001850 JP2010001850W WO2010106788A1 WO 2010106788 A1 WO2010106788 A1 WO 2010106788A1 JP 2010001850 W JP2010001850 W JP 2010001850W WO 2010106788 A1 WO2010106788 A1 WO 2010106788A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- base
- pgam4
- gene
- human
- mutation
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
Definitions
- the present invention relates to a technique that enables estimation of fertility and identification of the cause of infertility. Specifically, a method for detecting a deficiency or mutation of a gene correlated with fertility and testing / diagnosis fertility, and a kit, polynucleotide, and polypeptide that can be used in the method , And antibodies.
- infertility The cause of infertility is gender equality, but male infertility has many unexplained parts including the treatment method due to the complexity of spermatogenesis, and problems related to reproduction such as decreased number of human sperm and decreased fertility Many of the causes are unknown.
- IVF in vitro fertilization
- Non-Patent Document 1 studies on male infertility in mice have revealed the existence of many genes that affect fertility, and mutations in these genes contribute to male infertility in humans. It may have become.
- morphological changes that occur after meiosis in the spermatogenesis process are considered to include sperm cell-specific structural or functional changes in enzymes used for energy metabolism, and sperm-specific hexokinase (non-patent literature).
- Non-Patent Document 5 a knockout mouse (male) of glyceraldehyde 3-phosphate dehydrogenase becomes infertile, and sperm motility is observed. Therefore, abnormalities in enzyme functions of these sperm-specific glycolytic systems cause infertility. The possibility is suggested.
- Phosphoglycerate Mutase family member (PGAM) in mice is encoded by two genes, Pgam-1 and Pgam-2, and forms three types of isozymes consisting of B-type, M-type homozygous, and heterogeneous PGAM. Three types of isozymes are detected in the testes of grown mice, but no M-type isozymes are observed in the testes of newborn mice, and M-type is observed from 14-16 days after birth. (Refer nonpatent literature 9.). At the transcriptional level, type B is strong in the brain and kidney, moderately expressed in the liver, thyroid, muscle, and heart, and type M is strong in muscle and testicles, and is moderately expressed in the heart and lungs. (See Non-Patent Document 10).
- PGAM1 B type
- PGAM2 M type
- Non-Patent Document 11 PGAM4 (PGAM3, PGAM-B) containing no intron exists as a B-type isozyme
- M-type PGAM is considered to be expressed in addition to B-type, but many of the genes specifically expressed in testis do not contain introns (see Non-Patent Documents 13 and 14). , Suggesting the function of PGAM4 in the testis.
- hgnc_id 21731> McCarrey, 1 outside, Nature, 1987, Vol. 326, No. 6112, pages 501-505. Dahl, 4 others, Genomics, 1990, Vol. 8, No. 2, pp. 225-232.
- An effective genetic test / diagnosis method for diagnosing male infertility has not yet been established.
- the causes of male infertility range from deletion of germ cells themselves to infertility of sperm. Therefore, in order to establish an effective treatment method according to a disease state, a method capable of specifying the cause of various disease states is desired.
- the present invention has been made in view of the above problems, fertility test based on the estimation of fertility possibility based on the enzyme function involved in energy supply in sperm movement, and identification of the cause of infertility An object is to provide a diagnostic method.
- testis-specific PGAM4 functionally decreases, the energy supply in sperm movement decreases, and the probability of reaching fertilization decreases.
- Testis-type PGAM4 molecule is related to fertility
- mutation of PGAM4 gene causes (or is likely to cause) male infertility
- human PGAM4 gene sequence is analyzed
- human PGAM4 gene is related to male infertility
- the present invention has the following configuration.
- a polynucleotide comprising a base sequence represented by SEQ ID NO: 1, wherein the base at position 138 is substituted with cytosine.
- a polypeptide comprising an amino acid sequence encoded by the polynucleotide according to (5) or (6) above.
- a human fertility test kit comprising a reagent for detecting the presence or absence of a deletion or mutation in the human PGAM4 gene.
- the reagent for detecting the presence or absence of a deletion or mutation of the human PGAM4 gene is a group consisting of the 75th base, the 138th base, and the 539th base of the translation region of the human PGAM4 gene.
- the fertility test / diagnosis kit according to (10) wherein the presence or absence of a mutation of one or more selected bases can be detected.
- the fertility test / diagnosis method includes a detection step of detecting the presence or absence of a human PGAM4 gene deletion or mutation in a biological sample collected from a human.
- Human PGAM4 gene deficiency and specific base mutations are highly correlated with male infertility. Therefore, it is possible to estimate fertility and identify the cause of infertility by collecting a biological sample from the subject and using this biological sample to examine whether the subject's PGAM4 gene is defective or mutated. Become.
- SEQ ID NO: 1 is obtained by extracting only the translation region from the base sequence of the transcription product of the wild-type PGAM4 gene registered in GenBank with the accession number NC — 0000239.9. As shown in SEQ ID NO: 1, the wild type human PGAM4 gene has a translation region consisting of 765 bp. SEQ ID NO: 2 shows the deduced amino acid sequence of wild-type human PGAM4 protein. According to the human genome resource constructed by the Human Genome Project, the human PGAM4 gene is located on the long arm of the human X chromosome (Xq13).
- substitution mutations in the human PGAM4 gene are likely to cause infertility due to a decrease in the translation amount of normal PGAM4 protein.
- mutation means that a base is deleted, substituted, or inserted in the base sequence of a gene.
- the mutation of the PGAM4 gene detected in the detection process of the fertility test / diagnosis method according to the present invention is a mutation highly correlated with male infertility. Specifically, by detecting at least one of the four mutations described below, whether a human who has collected a biological sample used in the detection process is likely to become fertile or not. If it is already diagnosed, it can be tested whether the cause of infertility is due to a mutation in the PGAM4 gene, and a doctor makes a diagnosis of fertility based on this test result be able to.
- the “base at the X position of the translation region of the PGAM4 gene” means “the base at the X position of the translation region of the human PGAM4 gene when the translation start codon adenine is the first base”. To do.
- the fertility test / diagnosis method according to the present invention it is particularly preferable to detect the base at position 75 or the base at position 539 in the translation region of the PGAM4 gene. This is because the correlation with fertility is higher. Moreover, in the fertility test / diagnosis method according to the present invention, one of the above mutations may be detected, or a plurality of mutations may be detected.
- the fertility test / diagnosis method uses these single nucleotide mutations as fertility genetic markers. For example, when these base mutations are not detected, it can be presumed that the subject from whom the biological sample used in the detection process has been collected is likely to have no problem with fertility. Moreover, when the test subject has already been diagnosed as an infertility patient, it can be determined that the cause of infertility is highly likely due to something other than a functional defect of the PGAM4 gene. On the other hand, when a mutation is detected, it is estimated that the subject has a low possibility of fertility.
- the use of the fertility test / diagnosis method of the present invention may cause the functional defect of the PGAM4 molecule due to the deletion or mutation of the PGAM4 gene. Can be determined to be high. Therefore, the disease can be cured at an early stage by giving such a subject appropriate treatment such as TSE-ICSI (Testicular sperm extraction-Intracytoplasmic sperm injection; testicular biopsy-microinsemination). That is, the fertility test method according to the present invention can be said to be a test method for the purpose of estimating fertility and identifying the cause of infertility, and diagnoses infertility based on the results of the method. Since the important information is provided above, the subject can be presented with a qualified choice among existing treatments. For this reason, the fertility test method according to the present invention can be preferably used in the diagnosis of low fertility or infertility.
- the biological sample used in the fertility test / diagnosis method according to the present invention is particularly limited as long as it is a sample collected from a human and can be expected to contain a nucleic acid or protein derived from the PGAM4 gene.
- a nucleic acid or protein derived from the PGAM4 gene For example, blood, serum, plasma, mucous membranes such as the inside of the cheek, semen, testicular tissue (eg, seminiferous tubules) collected from the subject by testicular biopsy, sperm cells, seminal plasma, etc. it can.
- the nucleic acid derived from the PGAM4 gene means genomic DNA of the PGAM4 gene, mRNA that is a transcription product of the gene, or the like.
- the protein derived from PGAM4 gene means PGAM4 molecule
- a biological sample such as semen, testicular tissue (eg, seminiferous tubule) collected from a subject by testicular biopsy, sperm cells, seminal plasma, etc. may be used.
- the seminal plasma is considered to contain a protein expressed in the sperm cell, which is released when the sperm cell is destroyed even if it does not contain the sperm cell.
- the biological sample may be used in the detection step as it is by appropriately diluting the biological sample, or DNA such as genomic DNA previously extracted from the biological sample may be used.
- DNA such as genomic DNA previously extracted from the biological sample
- cDNA synthesized from the RNA by reverse transcription reaction may be used in the detection step.
- a method for detecting a deletion or mutation of the human PGAM4 gene is not particularly limited, and various known methods used for detecting a mutation or polymorphism of the gene, etc.
- base sequence determination method based on Sanger method, invader method, Taqman probe method, SMMD method (Multiple Mutation Detection System), PCR-RFLP (polymerase chain reaction-restriction fragmentation method, fragmentation method)
- SMMD method Multiple Mutation Detection System
- PCR-RFLP polymerase chain reaction-restriction fragmentation method, fragmentation method
- a base extension method and a modified method thereof can be used. Since detection sensitivity and accuracy are excellent, it is preferable to use a probe or primer having a base sequence that specifically recognizes a mutation site, such as the invader method or the Taqman probe method.
- Probes and primers for detecting a deletion or mutation of the human PGAM4 gene can be designed and synthesized by a conventional method based on the human PGAM4 gene and its surrounding nucleotide sequences.
- the human PGAM4 gene and its surrounding nucleotide sequences are obtained from publicly known databases such as NCBI Human Genome Resources (NCBI Human Genome Resources: http://www.ncbi.nlm.nih.gov/genome/guide/human/). Those skilled in the art can easily obtain them.
- a primer or the like for detecting the presence or absence of a mutation at position 75 in the translation region of the PGAM4 gene using mRNA or cDNA or genomic DNA obtained from the reverse transcription reaction is represented by SEQ ID NO: 3.
- the 101st base is substituted from guanine to cytosine, and consists of 10 to 100 consecutive base sequences containing the 101st base and a homologous or complementary base sequence.
- Polynucleotides can be used.
- a primer or the like for detecting the wild type in which no mutation has occurred at the 75th base it is also a polynucleotide comprising the base sequence represented by SEQ ID NO: 3, A polynucleotide comprising 10 to 100 consecutive base sequences containing bases and a homologous or complementary base sequence can be used.
- the base sequence represented by SEQ ID NO: 3 is a partial base sequence of the PGAM4 gene, and the 101st base corresponds to the 75th base of the translation region of the PGAM4 gene.
- a primer or the like for detecting the presence or absence of a mutation at position 539 in the translation region of the PGAM4 gene using mRNA or cDNA or genomic DNA obtained from the reverse transcription reaction is represented by SEQ ID NO: 5.
- the 101st base is substituted from guanine to adenine, and a polynucleotide comprising a 10-100 continuous base sequence containing the 101st base and a homologous or complementary base sequence is used. be able to.
- a primer or the like for detecting that there is no mutation in the base at position 539 10 to 100 containing the 101st base in the base sequence also represented by SEQ ID NO: 5
- a polynucleotide comprising a continuous base sequence and a homologous or complementary base sequence can be used.
- the base sequence represented by SEQ ID NO: 5 is a partial base sequence of the PGAM4 gene, and the 101st base corresponds to the 539th base of the translation region of the PGAM4 gene.
- a primer or the like for detecting the presence or absence of a mutation at position 138 of the translation region of the PGAM4 gene using mRNA or cDNA or genomic DNA obtained from the reverse transcription reaction is represented by SEQ ID NO: 4.
- the base sequence a polynucleotide in which the 101st base is substituted from adenine to cytosine and the base sequence is homologous or complementary to 10 to 100 consecutive base sequences including the 101st base is used. be able to.
- the base sequence represented by SEQ ID NO: 4 contains 10 to 100 containing the 101st base.
- a polynucleotide comprising a continuous base sequence and a homologous or complementary base sequence can be used.
- the base sequence represented by SEQ ID NO: 4 is a partial base sequence of the PGAM4 gene, and the 101st base corresponds to the 138th base of the translation region of the PGAM4 gene.
- the base sequence of the translation region of the human wild-type PGAM4 gene (SEQ ID NO: when the translation start codon adenine is the first base)
- a polynucleotide comprising 10 to 100 consecutive base sequences including the mutation site and a homologous or complementary base sequence can be used.
- a polynucleotide comprising 10 to 100 consecutive base sequences including the mutation site and a homologous or complementary base sequence can be used.
- the length of these polynucleotides is preferably 10 to 70 bases, more preferably 10 to 50 bases, and even more preferably 10 to 30 bases.
- the position of the base that can pair with the base of the mutation site is not particularly limited in the polynucleotide, but 1 to 5 bases from the 3 ′ end It is preferably within the range, and more preferably at the 3 ′ end.
- the present invention relates to a kit for examining fertility in humans, wherein a fertility test kit containing a reagent for detecting the presence or absence of a deletion or mutation of the human PGAM4 gene is used.
- a fertility test / diagnosis method can be performed more easily.
- the fertility test kit according to the present invention when the translation initiation codon adenine is the first base, the 75th base, the 138th base, or the 539th base of the translation region of the human PGAM4 gene. It is preferable that a reagent for detecting the mutation of the base at position is included, and it is more preferable that a reagent for detecting the mutation of the base at position 75 or the base at position 539 is included.
- the kit containing the reagent for detecting one type of mutation among these mutations may be sufficient, and the kit containing the reagent for detecting multiple types of mutation may be sufficient.
- Reagents for detecting these base mutations include, for example, a primer pair for amplifying a nucleic acid region containing the base by PCR and the like, and a base sequence for determining the base sequence of the obtained amplification product. And a determination reagent.
- the base sequence determination reagent include a homologous or complementary sequence of 10 to 100 consecutive base sequences including the mutation site in the base sequence of the human wild-type PGAM4 gene or the base sequence of the translation region described above. Examples thereof include a hybridization probe in which a polynucleotide comprising a base sequence is previously labeled with a fluorescent dye or the like.
- the method for detecting the deletion or mutation of the human PGAM4 gene is the PCR-RFLP method, it may be a restriction enzyme used in the RFLP method.
- the fertility test / diagnosis method and the fertility test kit according to the present invention are not particularly limited as long as they detect the presence or absence of a mutation that causes a functional defect in the human PGAM4 gene.
- the fertility test / diagnosis method and fertility test kit may detect that the human PGAM4 gene of the subject contains a mutation that causes a loss of function of the gene. It is also possible to detect that the human PGAM4 gene does not contain a mutation that causes a loss of function of the gene.
- the fertility test / diagnosis method and fertility test kit according to the present invention include the above-described mutation sites (hereinafter referred to as “mutation detection”) in the region within the human PGAM4 gene.
- mutation detection the presence or absence of the above-described substitution mutation may be detected by determining the base sequence of the region containing the base of “site”. For the determination of the base sequence, the Sanger method or various known techniques applying the Sanger method can be used.
- the fertility test kit includes a mutation detection site as a reagent for detecting the presence or absence of a deletion or mutation of the human PGAM4 gene in order to amplify the region containing the mutation detection site of the human PGAM4 gene.
- a set of primers designed to be sandwiched can be included. More specifically, the primer set includes a primer having a part or all of a base sequence upstream from the mutation detection site of the human PGAM4 gene and a base sequence downstream from the mutation detection site of the human PGAM4 gene. And a primer having a base sequence complementary to part or all.
- the region containing the base of the mutation detection site of the human PGAM4 gene is amplified as a DNA fragment.
- the base sequence can be easily determined by using, for example, ABI-PRISM 310 Genetic Analyzer (Applied Biosystems Inc.) according to the instruction manual.
- the fertility test kit includes a primer set for amplification of a DNA fragment and a primer used for determination of a base sequence as a reagent for detecting the presence or absence of a deletion or mutation of the human PGAM4 gene. You may go out.
- the length of the region sandwiched between the primers is preferably 5 kb or less, more preferably 3 kb or less, and even more preferably 2 kb or less. , 1.5 kb or less is particularly preferable.
- the primer used for determining the base sequence is preferably set at a position within 2 kb from the base of the mutation detection site, preferably set at a position within 1.5 kb, and within 1.0 kb. Is more preferably set to a position within 0.7 kb. With the above configuration, the base sequence can be accurately determined.
- the primer used for determining the base sequence is preferably set at a position separated by 20 bp or more from the base of the mutation detection site, more preferably set at a position separated by 30 bp or more, and separated by 40 bp or more. It is more preferable that the position is set, and it is particularly preferable that the position is set at a position separated by 50 bp or more. Moreover, it is preferable that the said primer group is what amplifies the area
- Each primer preferably has at least 10 bases, more preferably 15 bases or more, and more preferably 18 bases or more, the same base sequence as the PGAM4 gene or its periphery, or a complementary base sequence. It is preferable to have 20 bases or more. By increasing the length of the same (or complementary) base sequence as the PGAM4 gene or its surroundings, it is possible to reliably amplify only the target region including at least one of the mutation sites of the PGAM4 gene. .
- the primer set for example, a set consisting of a primer consisting of the base sequence represented by SEQ ID NO: 6 and a primer consisting of the base sequence represented by SEQ ID NO: 7 can be used.
- the base sequence of the primer that can be used is not limited to this sequence.
- a person skilled in the art can easily obtain the base sequence of the human PGAM4 gene and the surrounding base sequence from the above-described human genome resources and GenBank, and therefore, Oligo (registered) based on the obtained base sequence.
- Primers can be designed using trademarks such as National Bioscience Inc. or GENETYX (software development). Each primer can be synthesized by a known method such as a phosphoramidite method, and can be easily synthesized by using, for example, Applied Biosystems Inc. 392 synthesizer according to the instruction manual.
- Each primer may be labeled with a fluorescent label.
- the base sequence of the amplification region can be determined by the die primer method without using a radioisotope.
- the fluorescent label is not attached to each primer, the base sequence can be determined by the dye terminator method.
- the fertility test kit includes deoxyribonucleic acid composed of monomers A, T, G, and C, fluorescently labeled A, T, G, and C, in addition to the above primer set.
- a dideoxyribonucleic acid (so-called dye terminator) comprising a monomer, a polymerase, and the like may further be included.
- a fertility test / diagnosis method and a fertility test kit detect the presence or absence of a base substitution mutation at the mutation detection site of the human PGAM4 gene by an invader method. May be. Details of the invader method are described in a paper by Lyamichev et al. (Lyamichev V et al., Nat biotechnol. 17, 292, 1999), which is incorporated herein by reference.
- FIG. 1 is a schematic diagram illustrating the principle of the invader method.
- an invader oligo 2 and an allele oligo 3 which are non-fluorescently labeled probes and a fret probe 5 which is a fluorescently labeled probe are used.
- the invader probe 2 has a base sequence complementary to the target gene 1 and is designed so that the base at the 3 ′ end corresponds to the mutation (or single nucleotide polymorphism) detection site 1a of the target gene 1 ( It is not a complementary base to any base).
- the allele oligo 3 has a base sequence complementary to the flap 3b, which is a base sequence irrelevant to the target gene 1, and a target gene 1, and the 5 ′ terminal base is a mutation (or one) of the target gene 1.
- Nucleotide polymorphism A nucleotide 3a designed to complement the detection site 1a is linked.
- the flap 3b is linked to the 5 ′ end of the nucleotide 3a.
- the invader probe 2 enters only one base under the allele oligo 3. Then, the flap endonuclease (also called “clear base”) 4 recognizes this invasion structure and cleaves the allele oligo 3 at the 3 ′ side of the overlapped base. As a result, a flap free body 3c in which the flap 3b and the mutation detection site are linked is generated.
- the fret probe 5 is composed of a nucleotide 5a capable of hybridizing with itself at the 5 'end side and hybridizing with the flap 3b at the 3' end side, a fluorescent dye 5b, and a quencher (luminescence inhibitor) 5c.
- the nucleotide 5a has a base sequence complementary to the flap educt 3c at the 3 'end.
- the fluorescent dye 5b is bound to the 5 ′ end of the nucleotide 5a.
- the fluorescence of the fluorescent dye 5b is suppressed by the quencher 5c.
- the flap free body 3c hybridizes to such a fret probe 5
- a 3 entry structure is formed again at the mutation detection site of the flap free body 3c.
- the above-described flap endonuclease 4 recognizes this invasion structure again, and the 5 ′ end portion of the fret probe 5 is cleaved.
- the fluorescent dye 5b bonded to the 5 ′ end of the fret probe 5 is released and fluorescence is generated.
- the fertility test / diagnosis method and fertility test kit may detect the presence or absence of a human PGAM4 gene deletion or mutation by the invader method.
- the fertility test kit preferably includes an invader probe 2, an allele oligo 3, a fret probe 5, and the like as reagents for detecting the presence or absence of a human PGAM4 gene deletion or mutation.
- the invader probe 2 When fluorescence is generated when there is a substitution mutation, the invader probe 2 has a base sequence complementary to the human PGAM4 gene, and the 3 ′ terminal base is a mutant type of the mutant PGAM4 gene. Designed to correspond to a base (but not complementary).
- nucleotide 3a of allele oligo 3 has a base sequence complementary to the human PGAM4 gene, and is designed so that the base at the 5 'end is complementary to the above mutant base of the mutant PGAM4 gene.
- the fret probe 5 is a flap free body 3c that is cleaved by the flap endonuclease 4 when the invader probe 2 and the allele oligo 3 are hybridized with the mutant PGAM4 gene to form an invasion structure by the invader probe 2. Designed to be detectable.
- the 3 ′ end of the invader probe 2 enters the 5 ′ end of the nucleotide 3a hybridized with the target gene. 3c is cut out and fluorescence is generated.
- the test subject's PGAM4 gene is wild-type, no invasion structure is formed by the terminal portion of the invader probe 2, so that nucleotide 3c is not cut out and thus fluorescence does not occur.
- the fluorescence is generated when the PGAM4 gene of the subject is a substitution mutation type.
- the present invention is not limited to this, and the fluorescence is generated when the PGAM4 gene of the subject is a wild type.
- the fluorescence may be suppressed, or various modifications may be made such as using different fluorescent dyes for the wild type and the mutant type.
- the configuration for determining the presence or absence of a substitution mutation by examining the sense strand (codon-encoding strand) of the PGAM4 gene has been described in detail, but the same applies by examining the antisense strand. Needless to say, it is possible to make a judgment.
- the fertility test / diagnosis method and fertility test kit according to the present invention may detect the presence or absence of a mutation causing a functional defect in the human PGAM4 gene at the protein level. That is, the detection method and fertility test kit according to the present invention may determine whether or not normal human PGAM4 protein is expressed in human, and abnormal human PGAM4 protein is expressed. It may be determined whether or not there is.
- the normal protein is a human wild-type PGAM4 polypeptide, which means a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2.
- an abnormal protein is, for example, an amino acid sequence encoded by a polynucleotide having a mutation such as a single base substitution mutation in a polynucleotide comprising a base sequence of a translation region of a human wild-type PGAM4 gene, A polypeptide different from the polypeptide consisting of the amino acid sequence represented by No. 2 is meant.
- polynucleotide comprising the base sequence of the translation region of the human wild-type PGAM4 gene (base sequence represented by SEQ ID NO: 1) when the translation start codon adenine is the first base
- a polynucleotide comprising a base sequence in which the base at position 75 is substituted with cytosine, or a base sequence in which the base at position 539 is replaced with thymine.
- the method for detecting whether the human PGAM4 protein contained in the biological sample is a normal protein or an abnormal protein is not particularly limited.
- either a normal protein or an abnormal protein of the human PGAM4 protein is used.
- an antibody that recognizes only one it is possible to detect whether the human PGAM4 protein contained in the biological sample is a normal protein or an abnormal protein.
- the reagent binds to an abnormal protein of human PGAM4 and does not bind to a normal protein.
- the antibody may be used.
- Such an antibody can be prepared by selecting an antibody that does not cross normal protein of human PGAM4 from polyclonal antibodies and monoclonal antibodies prepared by a conventional method using human PGAM4 abnormal protein as an antigen. it can.
- such an antibody immunizes an experimental animal using the above-described human mutant PGAM4 polypeptide containing a substitution mutation of the amino acid at position 75 or 539 or a fragment thereof containing a mutation moiety as an antigen.
- animals can be immunized with free peptides.
- a macromolecular carrier eg, heal limpet hemocyanin (KLH) or tetanus toxide
- a peptide containing cysteine can be coupled to a carrier by a linker such as m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS).
- MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
- other peptides can be coupled to the carrier using more common linking agents such as glutaraldehyde.
- Animals such as rabbits, rats and mice can be immunized by intraperitoneal and / or intradermal injection of an emulsion containing free peptide or carrier-coupled peptide and Freund's adjuvant.
- booster injections are preferably performed at intervals of about 2 weeks.
- the antibody can be obtained by collecting blood from the immunized animal and extracting the IgG fraction from the serum. Further, the antibody titer is improved by purifying the antibody by a known technique.
- the antibody according to the present invention binds to the aforementioned human mutant PGAM4 polypeptide, but does not bind to human wild-type PGAM4 polypeptide.
- the antibody according to the present invention can be obtained by selecting antibodies that do not bind to human wild-type PGAM4 protein from the antibodies obtained by the above procedure.
- the fertility test / diagnosis method and fertility test kit according to the present invention include at least one base substitution at position 75 or position 539 among the above-described mutations.
- a human mutant PGAM4 protein is expressed in a biological sample collected from a human using an antibody that binds to the human mutant PGAM4 protein encoded by the human mutant PGAM4 gene and does not bind to the human wild-type PGAM4 protein. It may be what determines whether or not. Whether or not the human mutated PGAM4 protein is expressed using the above antibody is determined, and if it is determined that the human mutated PGAM4 protein is expressed in the subject, the substitution mutation described above has occurred in the human PGAM4 gene.
- the subject is less likely to be fertile or likely to be infertile.
- the cause of infertility originates in abnormality of human PGAM4 gene.
- the detection method and fertility test kit according to the present invention may determine whether or not normal human PGAM4 protein is expressed in human, and normal human PGAM4 The amount of protein expression may be determined. More specifically, the detection step of the fertility diagnostic method according to the present invention uses an antibody characterized in that it binds to human wild-type PGAM4 protein and does not bind to abnormal human PGAM4 protein. It may be one that detects whether or not human wild-type PGAM4 protein is present in the sample.
- the reagent binds to human wild-type PGAM4 protein and does not bind to an abnormal protein.
- Anti-PGAM4 antibody may be used.
- the presence or expression level of human PGAM4 protein is examined using an anti-PGAM4 antibody, and it is determined that the human PGAM4 protein is not expressed in the subject, or the subject in whom the expression level of the human PGAM4 protein has no gene mutation If it is determined that the human PGAM4 gene is deleted or mutated, it is estimated that the subject has a low possibility of fertility or a high possibility of infertility. can do.
- a test subject is infertile, it can be estimated that the cause of infertility is due to the fact that normal human PGAM4 protein is not expressed.
- the technique for detecting human wild-type PGAM4 protein or human mutant PGAM4 protein in a biological sample using an antibody is not particularly limited, and any known technique may be used. Examples thereof include Western blotting and ELISA (Enzyme-linked Immunosorbent Assay).
- the fertility diagnostic kit is a kit suitable for a fertility diagnostic method using Western blotting or ELISA
- the fertility diagnostic kit includes a reagent for detecting the presence or absence of a deletion or mutation of the human PGAM4 gene.
- an anti-globulin antibody labeled with a specific enzyme such as peroxidase necessary for the color reaction may be contained.
- control group (N 251) was a father of a child born to a pregnant woman at the obstetrics and gynecology clinic, and was a male with confirmed fertility. Informed consent was obtained from all donors that the samples were used for genomic DNA analysis (Osaka University Hospital Urology).
- Genomic DNA was isolated and prepared from blood samples or semen samples by protease treatment and phenol extraction (Sambrook J et al., Isolation of DNA from Mammalian Cells. New York: Cold Spring Harbor Press. 1989: pp. 9.16-9.21) .
- DNA amplified using GenomiPhi manufactured by GE Healthcare Bioscience was used.
- DNA containing a translation region encoding the protein of the PGAM4 gene was amplified according to the PCR reaction conditions shown in Table 2 using the primers F and R shown in Table 1.
- Primer F was designed such that the 5 ′ terminal base hybridizes with the base at the ⁇ 98th position when the translation start codon adenine is the first base position in the base sequence of the PGAM4 gene. It is a primer.
- the primer R is a primer designed so that the base at the 5 ′ end hybridizes with the base at the 850th position when the adenine of the translation initiation codon is the first base in the base sequence of the PGAM4 gene. It is.
- the obtained PCR amplified fragment was purified by AMPure (Agencourt Bioscience). Using this purified PCR amplified fragment as a template, sequencing reaction was performed using the primers used when the amplicon was amplified. Specifically, a BigDye (registered trademark) Terminator V3.1 Cycle Sequencing Kit (manufactured by Applied Biosystems) was used, and a reaction product purified by CleanSEQ (manufactured by Agencourt Bioscience) (ABI-PRISM 3730GeneticAGeneticA) (Applied Biosystems). The base sequence was determined by comparing the determination results in both directions.
- AMPure Anagencourt Bioscience
- the appearance rate of the substitution mutation of the 75th base was particularly high, and the correlation with male infertility was high.
- the present invention can be suitably used in the pharmaceutical field and the medical field.
- the known invention SCOT-t gene Patent No. 4422993
- PRM2 gene Patent No.
- Sex chromosome abnormality (Y chromosome mutation) is known as the cause of male infertility, and its frequency of occurrence is 5-10%. In developed countries, examination of sex chromosome abnormality is a cause diagnosis of male infertility patients. It is done in routine.
- the kit containing the present invention can identify more than 10% of the causative genes of male infertility, and it can be used in clinical settings to select infertility treatments and counseling patients based on scientific evidence. It is expected to be used by routines as a useful tool.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
一方、精子形成過程の減数分裂後に起こる形態学的変化には、エネルギー代謝に利用される酵素において、精子細胞特異的な構造もしくは機能変化が認められるとされ、精子特異的なhexokinase(非特許文献2参照。)、phosphoglucose isomerase(非特許文献3参照。)、aldolase(非特許文献4参照。)、glyceraldehyde 3-phosphate dehydrogenase(非特許文献5参照。)、phosphoglycerate kinase(非特許文献6参照。)、phosphoglycerate mutase(非特許文献7参照。)、enolase(非特許文献8参照。)などが活性化される。非特許文献5では、glyceraldehyde 3-phosphate dehydrogenaseのノックアウトマウス(オス)が不妊となり、精子の運動不良が認められることから、これら精子特異的な解糖系の酵素機能における異常は不妊の原因となる可能性が示唆される。
本発明は、上記課題に鑑みてなされたものであり、精子運動におけるエネルギー供給に関わる酵素機能に基づいた妊孕可能性の推定、及び不妊症の原因の同定を可能にする妊孕性検査・診断方法を提供することを目的とする。
(1)ヒトから採取された生体サンプルについて、ヒトPGAM4遺伝子の欠損又は変異の有無を検出する検出工程を有し、前記検出工程において、翻訳開始コドンのアデニンを第1位の塩基としたときに、ヒトPGAM4遺伝子の翻訳領域の、第75位の塩基、第138位の塩基、及び第539位の塩基からなる群より選択される1以上の塩基の変異の有無を検出する、妊孕性検査・診断方法。
(2)前記検査・診断方法の検出行程において、ヒトPGAM4遺伝子の翻訳領域の、第75位の塩基及び第539位の塩基からなる群より選択される1以上の変異の有無を検出する、妊孕性検査・診断方法。
(3)下記の(a)又は(b)の塩基配列:
(a)配列番号3で表される塩基配列において、101番目の塩基がグアニンからシトシンに置換されており、当該101番目の塩基を含む10~100の連続した塩基配列;
(b)前記(a)の塩基配列と相補的な塩基配列;
からなるポリヌクレオチド。
(4)下記の(c)又は(d)の塩基配列:
(c)配列番号5で表される塩基配列において、101番目の塩基がグアニンからアデニンに置換されており、当該101番目の塩基を含む10~100の連続した塩基配列;
(d)前記(c)の塩基配列と相補的な塩基配列;
からなることを特徴とするポリヌクレオチド。
(5)配列番号1で表される塩基配列において、ヒトPGAM4遺伝子の翻訳領域の第75位の塩基又は第539位の塩基が置換されており、この置換された塩基を含む10~100の連続した塩基配列と、相同的又は相補的な塩基配列からなるポリヌクレオチド。
(6)配列番号1で表される塩基配列からなるポリヌクレオチドにおいて、第138位の塩基がシトシンに置換された塩基配列からなる、ポリヌクレオチド。
(7)上記(5)又は(6)に記載のポリヌクレオチドによってコードされるアミノ酸配列からなる、ポリペプチド。
(8)上記(5)に記載のポリヌクレオチドによってコードされるアミノ酸配列からなるポリペプチドと結合し、かつ、配列番号2で表されるアミノ酸配列からなるポリペプチドと結合しない、抗体。
(9)ヒトから採取された生体サンプルについて、発現しているPGAM4ポリペプチドの変異の有無を、上記(8)に記載の抗体を使用することで検出する検出工程を有する、妊孕性検査・診断方法。
(10)ヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬を含む、ヒトの妊孕性検査キット。
(11)前記ヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬が、ヒトPGAM4遺伝子の翻訳領域の第75位の塩基、第138位の塩基、及び第539位の塩基からなる群より選択される1以上の塩基の変異の有無を検出することができる、上記(10)記載の妊孕性検査・診断キット。
(12)前記試薬が、抗PGAM4抗体である、請求項11記載の妊孕性検査・診断キット。
(13)前記試薬が、ヒトPGAM4遺伝子の変異検出部位の塩基を含む領域を増幅することができるプライマーセットである、上記(11)記載の妊孕性検査キット。
各プライマーは、たとえばホスホロアミダイト法等の公知の方法によって合成することができ、たとえばApplied Biosystems Inc.の392型シンセサイザー等を取扱説明書に従って使用することによって簡単に合成することができる。
一方、各プライマーに蛍光標識が付されていない場合、ダイターミネータ法によって塩基配列を決定することができる。この場合、上記妊孕性検査キットには、上記のプライマーの組に加えて、A、T、G、Cの各単量体からなるデオキシリボ核酸、蛍光標識されA、T、G、Cの各単量体からなるジデオキシリボ核酸(所謂ダイターミネータ)、及びポリメラーゼ等がさらに含まれていてもよい。
インベーダープローブ2は、ターゲット遺伝子1と相補的な塩基配列を有し、かつ、3’末端の塩基がターゲット遺伝子1の変異(又は一塩基多型)検出部位1aと対応するように設計される(いずれの塩基とも相補的な塩基ではない)。一方、アレルオリゴ3は、ターゲット遺伝子1とは無関係な塩基配列であるフラップ3bと、ターゲット遺伝子1と相補的な塩基配列を有し、かつ、5’末端の塩基がターゲット遺伝子1の変異(又は一塩基多型)検出部位1aに相補するように設計されたヌクレオチド3aとが連結したものである。ここで、フラップ3bは、ヌクレオチド3aの5’末端側に連結されている。
このように設計されたインベーダープローブ2とアレルオリゴ3をターゲット遺伝子1とハイブリダイゼーションさせると、ターゲット遺伝子1に対してアレルオリゴ3とインベーダープローブ2が重なり合った構造をとりながらハイブリダイズし、変異検出部位1aにおいてインベーダープローブ2がアレルオリゴ3の下に1塩基のみ侵入する。すると、フラップエンドヌクレアーゼ(「クリアベース(cleavase)」ともいう)4がこの侵入構造を認識し、アレルオリゴ3を重なった塩基の3’側で切断する。その結果、フラップ3bと変異検出部位とが連結したフラップ遊離体3cが生成される。
フレットプローブ5は、5’末端側が自身とハイブリダイゼーションでき、かつ、3’末端側がフラップ3bとハイブリダイゼーションできるヌクレオチド5aと、蛍光色素5bと、クエンチャー(発光抑制体)5cとからなる。ここで、ヌクレオチド5aは、 3’末端がフラップ遊離体3cと相補的な塩基配列となっている。また、蛍光色素5bは、ヌクレオチド5aの5’末端に結合している。ただし、フレットプローブ5においては、クエンチャー5cにより蛍光色素5bの蛍光が抑制されている。
このようなフレットプローブ5に対してフラップ遊離体3cがハイブリダイゼーションすると、フラップ遊離体3cの変異検出部位について、再び3進入構造が形成される。その結果、上述のフラップエンドヌクレアーゼ4がこの侵入構造を再び認識し、フレットプローブ5の5’末端部分が切断される。その結果、フレットプローブ5の5’末端に結合していた蛍光色素5bが遊離し、蛍光が生じる。
上記の構成により、被験者のPGAM4遺伝子において上記の塩基が変異型置換している場合は、ターゲット遺伝子にハイブリダイズしたヌクレオチド3aの5’末端にインベーダープローブ2の3’末端が侵入することにより、ヌクレオチド3cが切り出されて蛍光が生じる。一方、被験者のPGAM4遺伝子が野生型である場合は、インベーダープローブ2の末端部分による侵入構造が形成されないのでヌクレオチド3cが切り出されないため蛍光が生じない。
なお、上記の各方法において、PGAM4遺伝子のセンス鎖(コドンをコードする側の鎖)を調べることによって置換変異の有無を判定する構成について詳細に説明したが、アンチセンス鎖を調べることによっても同様に判定することができるのはいうまでもない。
一般的には、動物は遊離ペプチドによって免疫化することができる。ただし、遊離ペプチドを高分子キャリア(たとえば、ヒーホールリンペットヘモシアニン(KLH)または破傷風トキシド)にカップリングすることによって効率的に免疫化できるようになる場合もある。たとえば、システインを含有するペプチドは、m-マレイミドベンゾイル-N-ヒドロキシスクシンイミドエステル(MBS)のようなリンカーによってキャリアにカップリングすることができる。一方、他のペプチドは、グルタルアルデヒドのようなより一般的な連結剤を使用してキャリアにカップリングすることができる。
ウサギ、ラット及びマウスのような動物は、遊離ペプチドまたはキャリア-カップリングペプチドと、Freundのアジュバントとを含むエマルジョンを腹腔内及び/または皮内に注射することにより免疫化することができる。ELISAにより検出できる程度に有用な力価の抗ペプチド抗体を得るためには、約2週間の間隔で追加免疫注射を行うことが望ましい。
そして、免疫化された動物から血液を採取し、血清からIgG画分を抽出することにより抗体を得ることができる。また、抗体を公知の技術によって精製することにより、抗体の力価が向上する。
本発明に係る抗体は、上述したヒト変異型PGAM4ポリペプチドに結合する一方で、ヒト野生型PGAM4ポリペプチドには結合しないものである。それゆえ、上記の手順によって得られた抗体のうち、ヒト野生型PGAM4タンパク質と結合しないものを選出することによって、本発明に係る抗体を得ることができる。上記の選出を容易にするためには、動物に注射する抗原ペプチドとして、ヒト変異型PGAM4ポリペプチドの変異部分とその周辺のアミノ酸配列からなる10残基程度のオリゴペプチドを選択することが望ましい。
上記抗体を用いてヒト変異型PGAM4タンパク質が発現しているか否かを調べ、被験者においてヒト変異型PGAM4タンパク質が発現されていると判定された場合は、ヒトPGAM4遺伝子に上述した置換変異が生じていることが強く示唆され、同時に、その被験者は、妊孕可能性が低い、あるいは不妊症の可能性が高いと推定することができる。また、被験者が不妊症の場合は、不妊症の原因がヒトPGAM4遺伝子の異常に起因していると推定することができる。
より具体的には、本発明に係る妊孕性診断方法の検出工程が、ヒト野生型PGAM4タンパク質と結合し、かつ、異常ヒトPGAM4タンパク質と結合しないことを特徴とする抗体を用いることにより、生体サンプル中にヒト野生型PGAM4タンパク質が存在しているか否かを検出するものであってもよい。また、本発明に係る妊孕性診断キットに含まれるヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬として、ヒト野生型PGAM4タンパク質と結合し、かつ、異常タンパク質と結合しないことを特徴とする抗体(抗PGAM4抗体)を用いてもよい。
抗PGAM4抗体を用いてヒトPGAM4タンパク質の発現の有無や発現量を調べ、被験者においてヒトPGAM4タンパク質が発現していないと判定された場合や、ヒトPGAM4タンパク質の発現量が遺伝子変異が生じていない被験者よりも少ないと判定された場合には、ヒトPGAM4遺伝子が欠失または変異していることが示唆され、同時に、その被験者は、妊孕可能性が低い、あるいは不妊症の可能性が高いと推定することができる。また、被験者が不妊症の場合には、不妊症の原因が正常なヒトPGAM4タンパク質が発現していないことによるものと推定することができる。
妊孕性診断キットがウェスタンブロッティングまたはELISAを利用する妊孕性診断方法に好適なキットである場合、妊孕性診断キットには、ヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬として、抗ヒト野生型PGAM4タンパク質抗体又は抗ヒト変異型PGAM4抗体に加えて、発色反応に必要なペルオキシダーゼ等の特異的酵素で標識した抗グロブリン抗体が含まれていてもよい。
[解析対象者]
非閉塞性不妊症の日本人男性被験者(N=383)を、精子形成の欠損の程度に基づいてサブグループに分割した。これらの不妊症被験者のうち、13%は非閉塞性無精子症であり、31%は重症精子過少症(<5×106細胞/mL)であり、33%が運動無力症であり、残り23%が形態的に異常のないものであった。遺伝的要因を調べたところ、これらの被験者は何れも原発性特発性不妊症であった(Guideline for sperm donation. Fertil Steril. 2004: 82(suppl 1): S9 -S12)。コントロール群(N=251)は産婦人科医院にいる妊婦のもとに生まれた子供の父親であり、妊孕性が確認された男性とした。全ての提供者からは、サンプルがゲノムDNA解析に使用される旨のインフォームドコンセントを取得した(大阪大学病院泌尿器科)。
以下の各工程では、特に断りがない限り、常法又はキットに添付されている取扱説明書に従って各処理を行った。
ゲノムDNAは、プロテアーゼ処理とフェノール抽出により血液サンプル又は精液サンプルから単離し調製した(Sambrook J et al., Isolation of DNA from Mammalian Cells. New York: Cold Spring Harbor Press. 1989: pp. 9.16-9.21)。血液由来ゲノムDNAはGenomiPhi(GEヘルスケアバイオサイエンス社製)を用いて増幅したDNAを使用した。
PGAM4遺伝子のタンパク質をコードする翻訳領域を含むDNAを、表1に示したプライマーF及びプライマーRを用いて、表2に示したPCR反応条件に従って増幅した。
なお、プライマーFは、5’末端の塩基が、PGAM4遺伝子の塩基配列において、翻訳開始コドンのアデニンを第1位の塩基とした場合の第-98位の塩基とハイブリダイズするように設計されたプライマーである。一方、プライマーRは、5’末端の塩基が、PGAM4遺伝子の塩基配列において、翻訳開始コドンのアデニンを第1位の塩基とした場合の第850位の塩基とハイブリダイズするように設計されたプライマーである。
不妊症被験者及び妊孕性確認被験者のそれぞれについて、プライマーFとRで増幅されるアンプリコンの塩基配列を解析したところ、表3に示すように、置換変異が合計4個検出された。
このうち、アミノ酸の変化を伴う置換変異は2個であり、このうちの1個は妊孕性確認被験者にも検出されたが、残る1個は妊孕性確認被験者からは全く検出されなかった。また、妊孕性確認被験者からも検出された2個の置換変異のうちの1個は、不妊症被験者に有意に多かった。
一方、アミノ酸の変化を伴わない2個の置換変異のうち、1個は妊孕性確認被験者にも検出されたが、残る1個は妊孕性確認被験者からは全く検出されなかった。
これらの結果から、妊孕性確認被験者からは全く検出されなかった2個の置換変異と、不妊症被験者に有意に多かった1個の置換変異が、妊孕性との相関性があることが確認された。以下、この3個の置換変異について、それぞれ説明する。
Claims (13)
- ヒトから採取された生体サンプルについて、ヒトPGAM4遺伝子の欠損又は変異の有無を検出する検出工程を有し、
前記検出工程において、ヒトPGAM4遺伝子の翻訳領域の、第75位の塩基、第138位の塩基、及び第539位の塩基からなる群より選択される1以上の塩基の変異の有無を検出する、妊孕性検査方法。 - 前記検出工程において、ヒトPGAM4遺伝子の翻訳領域の、第75位の塩基及び第539位の塩基からなる群より選択される1以上の変異の有無を検出する、請求項1記載の妊孕性検査方法。
- 下記の(a)又は(b)の塩基配列:
(a)配列番号3で表される塩基配列において、101番目の塩基がグアニンからシトシンに置換されており、当該101番目の塩基を含む10~100の連続した塩基配列;
(b)前記(a)の塩基配列と相補的な塩基配列;
からなるポリヌクレオチド。 - 下記の(c)又は(d)の塩基配列:
(c)配列番号5で表される塩基配列において、101番目の塩基がグアニンからアデニンに置換されており、当該101番目の塩基を含む10~100の連続した塩基配列;
(d)前記(c)の塩基配列と相補的な塩基配列;
からなるポリヌクレオチド。 - 配列番号1で表される塩基配列からなるポリヌクレオチドにおいて、第75位の塩基がシトシンに置換された塩基配列又は第539位の塩基がアデニンに置換された塩基配列からなる、ポリヌクレオチド。
- 配列番号1で表される塩基配列からなるポリヌクレオチドにおいて、第138位の塩基がシトシンに置換された塩基配列からなる、ポリヌクレオチド。
- 請求項5又は6に記載のポリヌクレオチドによってコードされるアミノ酸配列からなる、ポリペプチド。
- 請求項5に記載のポリヌクレオチドによってコードされるアミノ酸配列からなるポリペプチドと結合し、かつ、配列番号2で表されるアミノ酸配列からなるポリペプチドと結合しない、抗体。
- ヒトから採取された生体サンプルについて、発現しているPGAM4ポリペプチドの変異の有無を、請求項8に記載の抗体を使用することで検出する検出工程を有する、妊孕性検査方法。
- ヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬を含む、ヒトの妊孕性検査キット。
- 前記ヒトPGAM4遺伝子の欠損又は変異の有無を検出するための試薬が、ヒトPGAM4遺伝子の翻訳領域の第75位の塩基、第138位の塩基、及び第539位の塩基からなる群より選択される1以上の塩基の変異の有無を検出することができる、請求項10記載の妊孕性検査キット。
- 前記試薬が、抗PGAM4抗体である、請求項11記載の妊孕性検査キット。
- 前記試薬が、ヒトPGAM4遺伝子の変異検出部位の塩基を含む領域を増幅することができるプライマーセットである、請求項11記載の妊孕性検査キット。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/256,860 US9194874B2 (en) | 2009-03-17 | 2010-03-15 | Test method for male fertility by detecting a mutation in the PGAM4 gene |
EP10753285.5A EP2410050B1 (en) | 2009-03-17 | 2010-03-15 | Fertility test method, polynucleotide, polypeptide and antibody |
JP2011504749A JP5713351B2 (ja) | 2009-03-17 | 2010-03-15 | 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-065110 | 2009-03-17 | ||
JP2009065110 | 2009-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010106788A1 true WO2010106788A1 (ja) | 2010-09-23 |
Family
ID=42739456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/001850 WO2010106788A1 (ja) | 2009-03-17 | 2010-03-15 | 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9194874B2 (ja) |
EP (1) | EP2410050B1 (ja) |
JP (1) | JP5713351B2 (ja) |
WO (1) | WO2010106788A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020520633A (ja) * | 2017-05-19 | 2020-07-16 | ジェン−プローブ・インコーポレーテッド | フラップエンドヌクレアーゼを含む乾燥組成物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258299A (ja) * | 1994-03-25 | 1995-10-09 | Oriental Yeast Co Ltd | Pgamアイソザイムに対する抗体 |
JP2007089409A (ja) | 2005-09-27 | 2007-04-12 | Osaka Univ | Tnp1遺伝子における変異の検出方法 |
JP2008067649A (ja) | 2006-09-14 | 2008-03-27 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、及びポリペプチド |
JP2008237114A (ja) | 2007-03-27 | 2008-10-09 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、ポリペプチド、発現ベクター、及び発現キット |
JP4229973B2 (ja) | 2002-02-14 | 2009-02-25 | 宏光 田中 | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 |
JP2009065882A (ja) | 2007-09-12 | 2009-04-02 | Osaka Univ | 妊孕性に関連するポリヌクレオチドおよびその利用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04229973A (ja) | 1990-12-27 | 1992-08-19 | Tanaka Kikinzoku Kogyo Kk | 多線束摺動ブラシ接点 |
-
2010
- 2010-03-15 JP JP2011504749A patent/JP5713351B2/ja active Active
- 2010-03-15 EP EP10753285.5A patent/EP2410050B1/en active Active
- 2010-03-15 WO PCT/JP2010/001850 patent/WO2010106788A1/ja active Application Filing
- 2010-03-15 US US13/256,860 patent/US9194874B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258299A (ja) * | 1994-03-25 | 1995-10-09 | Oriental Yeast Co Ltd | Pgamアイソザイムに対する抗体 |
JP4229973B2 (ja) | 2002-02-14 | 2009-02-25 | 宏光 田中 | 男性不妊関連遺伝子Scot−t変異と男性不妊の診断方法 |
JP4276691B2 (ja) | 2002-02-14 | 2009-06-10 | 宏光 田中 | 男性不妊関連遺伝子プロタミン−2変異と男性不妊の診断方法 |
JP2007089409A (ja) | 2005-09-27 | 2007-04-12 | Osaka Univ | Tnp1遺伝子における変異の検出方法 |
JP2008067649A (ja) | 2006-09-14 | 2008-03-27 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、及びポリペプチド |
JP2008237114A (ja) | 2007-03-27 | 2008-10-09 | Osaka Univ | 妊孕性診断キット、変異検出方法、ポリヌクレオチド、ポリペプチド、発現ベクター、及び発現キット |
JP2009065882A (ja) | 2007-09-12 | 2009-04-02 | Osaka Univ | 妊孕性に関連するポリヌクレオチドおよびその利用 |
Non-Patent Citations (25)
Title |
---|
"Symbol Report: PGAM4", HUMAN GENOME ORGANIZATION, 25 April 2005 (2005-04-25), Retrieved from the Internet <URL:http://www.genenames.org/data/hgnc_ data.php?hgnc_id=21731> |
BETRAN E. ET AL.: "Evolution of the phosphoglycerate mutase processed gene in human and chimpanzee revealing the origin of a new primate gene.", MOL. BIOL. EVOL., vol. 19, 2002, pages 654 - 663, XP055098308 * |
BROCENO, EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 227, no. 3, 1995, pages 629 - 635 |
BUEHR, JOURNAL OF REPRODUCTION AND FERTILITY, vol. 63, no. 1, 1981, pages 169 - 173 |
CHOW, M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, pages 910 - 914 |
DAHL, GENOMICS, vol. 8, no. 2, 1990, pages 225 - 232 |
DIERICK H. A. ET AL.: "A phosphoglycerate mutase brain isoform (PGAM1) pseudogene is localized within the human Menkes disease gene (ATP7A).", GENE, vol. 198, 1997, pages 37 - 41, XP004570074 * |
FORCE, JOURNAL OF ANDROLOGY, vol. 25, no. 5, 2004, pages 824 - 829 |
FRANCIS, M. J. ET AL., J. GEN. VIROL., vol. 66, 1985, pages 2347 - 2354 |
FUNDELE, DEVELOPMENTAL BIOLOGY, vol. 124, no. 2, 1987, pages 562 - 566 |
HIROMITSU TANAKA ET AL.: "Seiso Seishoku Saibo Tokuiteki Idenshi no single-nucleotide polymorphism(SNP) Kaiseki", PROCEEDINGS OF THE JAPAN SOCIETY OF ANDROLOGY THE ANNUAL MEETING, - 2007, pages 152 - 153, XP008167233 * |
HIROMITSU TANAKA: "Dansei Funinsho no Gen'in Idenshi no Dotei to Rinsho Oyo", KOSEI RODO KAGAKU KENKYUHI HOJOKIN HITO GENOME SAISEI IRYO TO KENKYU JIGYO HEISEI 15 NENDO SOKATSU KENKYU HOKOKUSHO, 2004, pages 19 - 22, XP008167206 * |
LYAMICHEV V ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 292 |
MATZUK, NATURE CELL BIOLOGY, vol. 4, no. 1, 2002, pages 41 - 549 |
MCCARREY, DEVELOPMENTAL GENETICS, vol. 19, no. 4, 1996, pages 321 - 332 |
MCCARREY, NATURE, vol. 326, no. 6112, 1987, pages 501 - 505 |
MIKI, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES OF AMERICA, vol. 101, no. 47, 2004, pages 16501 - 16506 |
MORI, MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 44, no. 1, 1996, pages 14 - 22 |
SAKODA, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 32, 1988, pages 16899 - 16905 |
SAMBROOK J ET AL.: "Isolation of DNA from Mammalian Cells", 1989, COLD SPRING HARBOR PRESS, pages: 9.16 - 9.21 |
See also references of EP2410050A4 * |
VEMUGANTI, DEVELOPMENTAL BIOLOGY, vol. 309, no. 1, 2007, pages 18 - 31 |
YASUSHI MIYAGAWA ET AL.: "Dansei Funinsho Kanja ni Okeru Seiso Seishoku Saibo Tokuiteki Idenshi SNP Kaiseki to sono Rinsho Oyo", PROCEEDINGS OF THE JAPAN SOCIETY OF ANDROLOGY THE ANNUAL MEETING, - 2008, pages 82 - 83, XP008167228 * |
YASUSHI MIYAGAWA ET AL.: "Dansei Funinsho to Seishi Keisei Idenshi", PROCEEDING OF THE JAPANESE SOCIETY OF ANIMAL MODELS FOR HUMAN DISEASES, vol. 20, 2004, pages 29 - 34, XP008167232 * |
ZHANG, GENE, vol. 264, no. 2, 2001, pages 273 - 279 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020520633A (ja) * | 2017-05-19 | 2020-07-16 | ジェン−プローブ・インコーポレーテッド | フラップエンドヌクレアーゼを含む乾燥組成物 |
JP2022002549A (ja) * | 2017-05-19 | 2022-01-11 | ジェン−プローブ・インコーポレーテッド | フラップエンドヌクレアーゼを含む乾燥組成物 |
US11952630B2 (en) | 2017-05-19 | 2024-04-09 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
JP7491885B2 (ja) | 2017-05-19 | 2024-05-28 | ジェン-プローブ・インコーポレーテッド | フラップエンドヌクレアーゼを含む乾燥組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2410050B1 (en) | 2017-06-21 |
US9194874B2 (en) | 2015-11-24 |
JPWO2010106788A1 (ja) | 2012-09-20 |
JP5713351B2 (ja) | 2015-05-07 |
EP2410050A1 (en) | 2012-01-25 |
US20120116243A1 (en) | 2012-05-10 |
EP2410050A4 (en) | 2013-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7000658B2 (ja) | 肝臓病変を評価する方法 | |
US9784742B2 (en) | Means and methods for non-invasive diagnosis of chromosomal aneuploidy | |
KR20210107719A (ko) | 자궁내막증과 연관된 미토콘드리아 dna 결실 | |
CN112534065A (zh) | Trbc使用的分子评估 | |
US10939868B2 (en) | Method of predicting rapid progression of fibrosis and therapy and reagents therefor | |
JP2008237204A (ja) | 疾患モデル動物、細胞、組織、精巣、交配用動物、生殖細胞生産方法、生殖細胞、培養細胞、スクリーニング方法、医薬組成物、妊孕性診断キット、検出方法、ポリヌクレオチド、ポリペプチド、及び抗体 | |
JP5713351B2 (ja) | 妊孕性検査方法、妊孕性検査キット、ポリヌクレオチド、ポリペプチド、及び抗体 | |
US20100292088A1 (en) | Methods and compositions for detecting genetic markers associated with primary ciliary dyskinesia | |
JP2010187556A (ja) | 妊孕性診断方法、妊孕性診断キット、ポリヌクレオチド、ポリペプチド、及び抗体 | |
KR20130041767A (ko) | 정상 안압 녹내장 질환 감수성 유전자 및 그 이용 | |
JP2014183839A (ja) | 哺乳動物における膵癌を診断するための診断キット、それを用いた検査方法および診断マーカー | |
KR102063486B1 (ko) | Rnf213 단일염기다형성과 한국인 모야모야병 발병 위험도의 연관성 | |
JP5897704B2 (ja) | ブラキスパイナ突然変異の検出 | |
WO2021243166A2 (en) | Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and systems and methods of use thereof | |
WO2006137487A1 (ja) | β遮断薬に対する反応性予測に有用な遺伝子多型 | |
Tıplamaz et al. | Presence of fetal DNA in maternal exhaled breath condensate | |
JP5493359B2 (ja) | 方法、キット、ポリヌクレオチドの妊孕可能性の推定又は不妊症の原因の同定のための使用、ポリペプチドの妊孕可能性の推定又は不妊症の原因の同定のための使用、及び抗体 | |
JP6516128B2 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット | |
RU2777086C1 (ru) | Способ преимплантационного генетического тестирования буллезного эпидермолиза | |
JP2010220586A (ja) | 妊孕性診断方法、妊孕性診断キット、ポリヌクレオチド、ポリペプチド、及び抗体 | |
JP5263919B2 (ja) | メタボリック症候群の検査方法 | |
JP2009065882A (ja) | 妊孕性に関連するポリヌクレオチドおよびその利用 | |
CN113186274A (zh) | Grpel1突变基因、检测其的引物、试剂盒和方法以及其用途 | |
JP4686713B2 (ja) | 関節リウマチの検査方法、関節リウマチ診断薬、及びそれに用いられるプライマー | |
CN113403378A (zh) | Timm13突变基因、检测其的引物、试剂盒和方法以及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10753285 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011504749 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2010753285 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010753285 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13256860 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |